NASDAQ:ARWRArrowhead Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $47.51 +3.00 (+6.74 %) (As of 07/13/2020 11:12 AM ET) Add Compare Share Today's Range$44.70Now: $47.51▼$47.9650-Day Range$31.58MA: $37.47▼$45.2552-Week Range$19.51Now: $47.51▼$73.72Volume498,408 shsAverage Volume1.18 million shsMarket Capitalization$4.84 billionP/E Ratio523.06Dividend YieldN/ABeta1.81 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $62.00, Arrowhead Pharmaceuticals has a potential upside of 31.9% from its current price of $46.99.Amount of Analyst CoverageArrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesArrowhead Pharmaceuticals has received 466 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArrowhead Pharmaceuticals has received 456 “underperform” votes. (Add your “underperform” vote.)Community SentimentArrowhead Pharmaceuticals has received 50.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote “Outperform” if you believe ARWR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold 44,877.53% more of their company's stock than they have bought. Specifically, they have bought $15,665.00 in company stock and sold $7,045,730.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions64.18% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($0.44) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is 522.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is 522.17, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.34.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 18.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR Previous Symbol CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone626-304-3400Debt Debt-to-Equity Ratio0.03 Current Ratio5.90 Quick Ratio5.90Price-To-Earnings Trailing P/E Ratio523.06 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$168.80 million Price / Sales28.64 Cash Flow$0.83 per share Price / Cash Flow57.43 Book Value$2.57 per share Price / Book18.49Profitability EPS (Most Recent Fiscal Year)$0.69 Net Income$67.97 million Net Margins6.86% Return on Equity2.61% Return on Assets2.08%Miscellaneous Employees116 Outstanding Shares101,770,000Market Cap$4.84 billion Next Earnings Date8/5/2020 (Confirmed) OptionableOptionable NASDAQ:ARWR Rates by TradingView Receive ARWR News and Ratings via Email Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions How has Arrowhead Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARWR stock has increased by 64.5% and is now trading at $46.99. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Arrowhead Pharmaceuticals? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arrowhead Pharmaceuticals. When is Arrowhead Pharmaceuticals' next earnings date? Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Arrowhead Pharmaceuticals. How can I listen to Arrowhead Pharmaceuticals' earnings call? Arrowhead Pharmaceuticals will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.09. The biotechnology company had revenue of $23.53 million for the quarter, compared to analyst estimates of $21.90 million. Arrowhead Pharmaceuticals had a return on equity of 2.61% and a net margin of 6.86%. View Arrowhead Pharmaceuticals' earnings history. What price target have analysts set for ARWR? 10 Wall Street analysts have issued 1-year price targets for Arrowhead Pharmaceuticals' shares. Their forecasts range from $29.00 to $81.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $62.00 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View analysts' price targets for Arrowhead Pharmaceuticals. Has Arrowhead Pharmaceuticals been receiving favorable news coverage? News articles about ARWR stock have trended very negative on Monday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Arrowhead Pharmaceuticals. Who are some of Arrowhead Pharmaceuticals' key competitors? Some companies that are related to Arrowhead Pharmaceuticals include Merck KGaA (MKGAF), Beigene (BGNE), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Mylan (MYL) and Perrigo (PRGO). View all competitors. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), Alliance Resource Partners (ARLP), Sasol (SSL), Sarepta Therapeutics (SRPT) and Advanced Micro Devices (AMD). Who are Arrowhead Pharmaceuticals' key executives? Arrowhead Pharmaceuticals' management team includes the following people: Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)Dr. Bruce D. Given, Chief Operating Officer (Age 65)Mr. Patrick O'Brien, Gen. Counsel (Age 55)Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.04%) and Defender Capital LLC. (0.01%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View institutional ownership trends for Arrowhead Pharmaceuticals. Which institutional investors are selling Arrowhead Pharmaceuticals stock? ARWR stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Michael S Perry, and Patrick O'brien. View insider buying and selling activity for Arrowhead Pharmaceuticals. Which institutional investors are buying Arrowhead Pharmaceuticals stock? ARWR stock was bought by a variety of institutional investors in the last quarter, including Defender Capital LLC.. View insider buying and selling activity for Arrowhead Pharmaceuticals. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $46.99. How big of a company is Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals has a market capitalization of $4.78 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe. What is Arrowhead Pharmaceuticals' official website? The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
